NAOMI KIGONDU: Open Payments
NPI 1518451152 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,316 in 62 payments from 8 companies in 2025. Trend: 2023 $773 · 2024 $973 · 2025 $1,316
Food & beverage: $1,316
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 13 | $334 |
| E.R. Squibb & Sons, L.L.C. | 13 | $245 |
| ABBVIE INC. | 15 | $195 |
| Otsuka America Pharmaceutical, Inc. | 11 | $166 |
| Noven Therapeutics, LLC | 3 | $144 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 4 | $76 |
| Axsome Therapeutics, Inc. | 2 | $30 |
Products named: ARISTADA, COBENFY, VRAYLAR, FANAPT, Xelstrym, ABILIFY MAINTENA, REXULTI, UZEDY.
Industry payments across NE — which companies pay providers there.
